Open AccessOn the strategy of using nonviral carriers in cancer gene therapy.
Author(s) -
A Sochanik,
S Szala
Publication year - 1996
Publication title -
acta biochimica polonica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.452
H-Index - 78
eISSN - 1734-154X
pISSN - 0001-527X
DOI - 10.18388/abp.1996_4497
Subject(s) - genetic enhancement , gene delivery , gene , delivery system , in vivo , recombinant dna , cancer , cancer research , dna , gene transfer , computational biology , biology , microbiology and biotechnology , genetics , pharmacology
Effectiveness and mode of therapeutic gene delivery in vivo as well as biological safety of such transfer must be improved before widespread application of gene therapy in the clinic becomes possible. Most research has so far focused on recombinant viral delivery systems. Clinical future seems to belong, however, to nonviral delivery systems. Such systems feature DNA complexed to lipid, protein, peptide or polymeric carriers with ligands allowing in vivo tissue targeting by the complex and nuclear translocation of the exogene. Nonviral gene carrier systems are discussed together with strategies of destroying cancer cells.